MA-VERACODE
6.10.2022 13:51:35 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform to include container security. This early access program for Veracode Container Security is now underway for existing customers. The new Veracode Container Security offering, designed to meet the needs of cloud-native software engineering teams, addresses vulnerability scanning, secure configuration, and secrets management requirements for container images.
Veracode Chief Product Officer, Brian Roche, said, “As developers embrace cloud-native computing practices, containers have become increasingly important for business efficiency. This launch helps close a substantial gap in the market for developer-friendly solutions that cover critical capabilities for container security. We are excited to bring this next enhancement of our platform to the market and empower customers to address security testing for more modern architectures and deployment styles.”
The Requirement for Container Security is Rapidly on the Rise
Containers are increasingly used to simplify software deployment and runtime environment configuration management. They comprise small, fast, portable units of software in which code is packaged so that an application can be run quickly and reliably in different computing environments—from the desktop to the cloud. They provide an ecosystem of repositories, orchestration technologies, and capabilities that address related issues, such as service-to-service communication and configuration management. Instantiated in pipelines from code, containers have the benefit of immutability, meaning they are not updated, reconfigured or patched in production. Instead, the underlying image is updated with new capabilities and redeployed, helping to improve efficiency in the production environment.
Despite the benefits of containers, they are affected by many of the same problems that traditionally plague physical production or virtual server hardware, such as vulnerabilities introduced through additional software, poorly managed secrets (like Amazon Web Services keys and credentials in Dockerfiles), and security misconfigurations. This has resulted in increased demand for products that address these issues and related problems, with the Global Container Security Market size expected to reach $3.9 billion by 2027*. Container security scanning analyzes container images against organizational or industry-specific standards to identify insecure processes, misconfigurations that could lead to a vulnerability, and inadequate authentication and access control.
Veracode Container Security Integrates into the Developer Environment
Many products already in the market are aimed at securing containers in runtime and offer limited support for developers, posing a major challenge for early remediation. Veracode’s solution instead integrates into the CI/CD (continuous integration and continuous delivery) pipeline and is available at the command line interface. Providing coverage for vulnerability detection and remediation, secrets management, and security configuration issues on the most popular operating systems, it delivers remediation advice to developers early in the software development life cycle so that insecure containers don’t ship to production.
Veracode Container Security results are available in a variety of formats based on the user’s choice, including text, JSON (JavaScript Object Notation), and Software Bill of Materials (CycloneDX, SWID [Software Identification Tagging], or SPDX [Software Packaging Data Exchange]), making them easy to integrate with other tools. Providing developers and their teams with the tools to meet their specific needs means they can find and fix vulnerabilities early in the lifecycle, giving them confidence that their containerized application environment is secure.
“Veracode Container Security will be instrumental for our developers to ensure that the workloads they deploy into our cloud are secure,” said the Director of Information Security at an automotive company. “Without this tool, it would take our team weeks to receive and action container results and these would only have been available in limited formats. Now, we’re excited to integrate findings into the pipeline before they even move into production, creating time and cost efficiencies for our business.”
To learn more about Container Security, read more here.
*Research and Markets, "Global Container Security Market Size, Share & Industry Trends Analysis Report By Component (Products and Services), By Services Type, By Organization Size, By Vertical, By Regional Outlook and Forecast, 2021-2027" report, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
